{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:21:32Z","timestamp":1790076092488,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.clinthera.2009.01.003","type":"journal-article","created":{"date-parts":[[2009,2,24]],"date-time":"2009-02-24T14:52:38Z","timestamp":1235487158000},"page":"177-189","source":"Crossref","is-referenced-by-count":52,"title":["Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study"],"prefix":"10.1016","volume":"31","clinical-trial-number":[{"clinical-trial-number":"nct00463918","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Helene","family":"Faessel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patanjali","family":"Ravva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.01.003_bib1","series-title":"WHO report on the global tobacco epidemic, 2008\u2013the MPOWER package","year":"2008"},{"key":"10.1016\/j.clinthera.2009.01.003_bib2","series-title":"Adolescent smoking statistics [American Lung Association Web site]","year":"2008"},{"key":"10.1016\/j.clinthera.2009.01.003_bib3","series-title":"Legacy First Look Report 3. Pathways to Established Smoking: Results from the 1999 National Youth Tobacco Survey","author":"Mowery","year":"2000"},{"key":"10.1016\/j.clinthera.2009.01.003_bib4","first-page":"1","article-title":"Global youth tobacco surveillance, 2000\u20132007","volume":"57","author":"Warren","year":"2008","journal-title":"MMWR Surveill Summ."},{"key":"10.1016\/j.clinthera.2009.01.003_bib5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/tc.11.3.252","article-title":"Tobacco use among youth: Across country comparison","volume":"11","year":"2002","journal-title":"Tob Control."},{"key":"10.1016\/j.clinthera.2009.01.003_bib6","first-page":"1","article-title":"Youth risk behavior surveillance\u2014United States, 2005","volume":"55","author":"Eaton","year":"2006","journal-title":"Morb Mortal Wkly Rep MMWR"},{"key":"10.1016\/j.clinthera.2009.01.003_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1054-139X(99)00024-5","article-title":"How many adolescents start smoking each day in the United States?","volume":"25","author":"Gilpin","year":"1999","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.clinthera.2009.01.003_bib8","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.neuropharm.2006.10.016","article-title":"Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenichne, an effective smoking cessation aid","volume":"52","author":"Rollema","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.clinthera.2009.01.003_bib9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0091-3057(01)00652-9","article-title":"Cellular mechanisms of nicotine addiction","volume":"70","author":"Dam","year":"2001","journal-title":"Pharmacol Biochem Behav."},{"key":"10.1016\/j.clinthera.2009.01.003_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/34413","article-title":"Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine","volume":"391","author":"Picciotto","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2009.01.003_bib11","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1099420","article-title":"Nicotine activation of alpha4* receptors: Sufficient for reward, tolerance, and sensitization","volume":"306","author":"Tapper","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2009.01.003_bib12","series-title":"Chantix [package insert]","year":"2008"},{"key":"10.1016\/j.clinthera.2009.01.003_bib13","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1177\/0091270006292624","article-title":"Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenichne, in healthy smokers","volume":"46","author":"Faessel","year":"2006","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2009.01.003_bib14","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1177\/0091270006290669","article-title":"Single-dose pharmacokinetics of varenichne, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers","volume":"46","author":"Faessel","year":"2006","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2009.01.003_bib15","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1177\/0091270006291837","article-title":"Pharmacokinetics, safety, and tolerabihty after single and multiple oral doses of varenichne in elderly smokers","volume":"46","author":"Burstem","year":"2006","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2009.01.003_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1124\/dmd.105.006767","article-title":"Metabolism and disposition of varenichne, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro","volume":"34","author":"Obach","year":"2006","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.clinthera.2009.01.003_bib17","series-title":"CDC growth chart of the United States","year":"2006"},{"key":"10.1016\/j.clinthera.2009.01.003_bib18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0031-3955(16)36251-4","article-title":"The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents","volume":"34","author":"Schwartz","year":"1987","journal-title":"Pediatr Clin North Am."},{"key":"10.1016\/j.clinthera.2009.01.003_bib19","series-title":"National Health and Nutrition Examination Survey, 2003\u20132004","year":"2006"},{"key":"10.1016\/j.clinthera.2009.01.003_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","article-title":"A size Standard for pharmacokinetics","volume":"30","author":"Holford","year":"1996","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.clinthera.2009.01.003_bib21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1126\/science.276.5309.122","article-title":"A general model for the origin of al-lometnc scaling laws in biology","volume":"276","author":"West","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2009.01.003_bib22","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1067\/mai.2000.109419","article-title":"Impact of developmental pharmacology on pediatric study design: Overcoming the challenges","volume":"106","author":"Kearns","year":"2000","journal-title":"J Allergy Clin Immunol."},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2009.01.003_bib23","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1038\/sj.ijo.0802805","article-title":"Body composition in adolescents: Measurements and metabolic aspects","volume":"28","author":"Rodr\u00edguez","year":"2004","journal-title":"Int J Obes Relat Metab Disord."},{"key":"10.1016\/j.clinthera.2009.01.003_bib24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000074246","article-title":"Annual changes in bone mineral content and body composition during growth","volume":"60","author":"Braillon","year":"2003","journal-title":"Horm Res."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T13:23:17Z","timestamp":1545398597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809000174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0149291809000174"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.01.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}